

**IN THE MATTER OF** \* **BEFORE THE**  
**RYANN TAYLOR, PHARM TECH** \* **STATE BOARD**  
**Respondent** \* **OF PHARMACY**  
**Registration No.: T17843** \* **Case No. PT-16-026**

\* \* \* \* \*

**FINAL CONSENT ORDER**

Based on information received and a subsequent investigation by the State Board of Pharmacy (the "Board"), and subject to Md. Code Ann., Health Occupations II (Health Occ. II) §§ 12-101, *et seq.*, (2014 Repl. Vol. II and 2017 Supp.) (the "Act"), on July 19, 2017, the Board charged **RYANN TAYLOR, PHARM TECH** (the "Respondent"), with violations of its Act. On November 29, 2017, a Case Resolution Conference was held with the Respondent, who was represented by Counsel, members of the Board, along with Board Counsel, and the Administrative Prosecutor in order to determine whether the matter could be resolved. As a result, the following settlement was reached.

**BACKGROUND**

The Board based its charges on the following facts that the Board had cause to believe are true:

1. At all times relevant hereto, the Respondent was registered to practice as a Pharm Tech in Maryland. The Respondent was first registered on March 29, 2016. The Respondent's registration expired on August 31, 2017.

2. At all times relevant hereto, the Respondent was employed as a Pharm Tech at a chain pharmacy in Riverdale, Prince George's County, Maryland, hereinafter the "Pharmacy."<sup>1</sup>

---

<sup>1</sup>The names of the individuals and facilities are confidential.

3. On or about June 4, 2016, the Board received documentation from the Pharmacy indicating that it had identified a theft or loss of controlled substances and had begun an investigation of the Respondent.

4. By documentation dated June 13, 2016, the Board received further information from the Pharmacy as follows:

- A. The Pharmacy reviewed video footage and observed the following:
- (1) On May 20, 2016, the pharmacist was seen removing a bottle of Oxycodone<sup>2</sup> from the safe and filling a script;
  - (2) The remaining pills were not immediately put in the safe but were left on production where the Respondent was observed removing the basket with other drugs in them and returning them to their shelves;
  - (3) When the Respondent returned, the bottle of Oxycodone was not returned to the pharmacist;
  - (4) On May 24, 2016, the Respondent was observed removing a prescription bag from the production table and was then seen removing its contents and tucking the contents under her lab jacket;
  - (5) The Respondent was then seen shielding herself with her lab jacket while making a concealing motion. After hanging up the jacket, the Respondent exited the pharmacy;

---

<sup>2</sup>Oxycodone is an opioid pain medication. An opioid is sometimes called a narcotic. Oxycodone is used to treat moderate to severe pain.

- (6) On May 26, 2016, the Respondent was observed removing several prescriptions from the production counter, appearing to consolidate the bags into one. The Respondent was observed at production placing a phone call on her cell phone, and then proceeding to the pick-up area;
- (7) Minutes later, two males appear to be waiting but did not enter the line until the Respondent had no customers in front of her;
- (8) The Respondent provided one of the males with a prescription, and, once the individuals left, the Respondent followed and was gone for five minutes;
- (9) On May 31, 2016, the Respondent was observed going to the pick-up window from production. A young female was observed pacing near the line but never entered the line until the Respondent was free, at which time, the Respondent gave the female a prescription bag and the female exited the pharmacy;

B. In an undated report, the Supervising Pharmacist at the Pharmacy relayed the following:

- (1) He was informed by "Corporate" that the Pharmacy could potentially have some discrepancies in Alprazolam<sup>3</sup>, 1 and 2 mg;

---

<sup>3</sup> Alprazolam is used to treat anxiety disorders, panic disorders, and anxiety.

- (2) During the course of the investigation, it was discovered that there were numerous instances where the Respondent modified the reports to reflect that the on-hand amounts of Alprazolam had been reset to either zero or reduced;
- (3) The ordering patterns for Alprazolam for the month of May were researched and it was determined that the drugs were ordered on the Respondent's shifts for several days;
- (4) Based on video surveillance, it was determined that there were several potential instances of the Respondent's concealing drugs upon her person;

C. On June 2, 2016, the Pharmacist-in-Charge discovered that the Respondent had given two prescriptions to persons to whom they did not belong, via the pick-up window;

D. It was also established that the Respondent was seen on video picking up a prescription at closing time from the production counter, walking near the trash can, and palming the prescription under her lab jacket and then leaving the Pharmacy;

E. Based upon the above, the Respondent was interviewed by the Pharmacy's Regional Loss Prevention Manager (RLPM), in the presence of the Pharmacist-in-Charge. The Respondent denied giving any prescriptions away. The Respondent then looked at her phone and replied "yes" when asked whether she needed to make a call. The Respondent then exited the office and used the phone

for approximately seven minutes, pacing in front of the store. The RLPM then informed the Respondent that they needed to finish the interview. The RLPM headed back to the office, whereupon the Respondent got in her car and drove out of the parking lot;

F. Based upon the original issue of an unnamed subject receiving controlled medication, the police were called and viewed the video footage. The RLPM provided the officer with the driver's license of the individual who picked up the medication;

G. The Respondent later sent a fax message that she had "quit" and would not be finishing the interview.

5. The Pharmacy filed a Drug Enforcement Administration (DEA) "Report of Theft or Loss of Controlled Substances" dated July 10, 2016, as follows, *inter alia*:

A. The Pharmacy stated that the loss was due to employee pilferage, and identified the Respondent;

B. The Pharmacy stated that the total loss was \$1,748;

C. The Pharmacy stated that the employee was terminated and that all loss prevention policy and procedures will be reviewed with the pharmacy team, including diligent inventory management, bag and smock checks, as well as no personal items allowed in the pharmacy;

D. The stolen drugs were listed as follows:

(1) Alprazolam, 1 mg 2087 tablets;

(2) Alprazolam, 2 mg 837 tablets;

- |     |                                |              |
|-----|--------------------------------|--------------|
| (3) | Oxycontin <sup>4</sup> , 20 mg | 60 tablets;  |
| (4) | Alprazolam, .05 mg             | 110 tablets. |

6. As a result of the above, the Board issued a Summary Suspension Order of the Respondent's registration on September 2, 2016. Although the Respondent requested a hearing, once hearing dates were set, the Respondent twice requested postponements, which the Board granted, and no hearing was held.

7. As set forth above, the Respondent violated Health Occ. II § 12-6B-09 (3), (8), and (27); §12-213 (25); and, COMAR 10.34.10 .01 B (3).

**CONCLUSIONS OF LAW**

Based upon the foregoing Findings of Fact, the Board finds that Respondent violated Health Occ. II § 12-6B-09 (3), (8), and (27); § 12-213 (25); and, COMAR 10.34.10 .01.B. (3).

**ORDER**

Based on the foregoing Findings of Fact, Conclusions of Law and agreement of the parties, it is this 12<sup>th</sup> day of July 2018 by a majority of a quorum of the Board,

**ORDERED** that the Respondent's registration shall be reinstated, provided that she is eligible to be reinstated;

**ORDERED** that, after the reinstatement, the Respondent's registration shall be

---

<sup>4</sup> OxyContin is a prescription narcotic pain reliever. Its active ingredient is oxycodone, a derivative of opium. When taken orally and as prescribed, it may last up to 12 hours.

suspended until September 2, 2018, at which time the Respondent may petition the Board to terminate the Suspension;


**ORDERED** that prior to the petition to terminate the Suspension, the Respondent shall submit to a comprehensive evaluation with a Board-approved substance abuse evaluator;

**ORDERED** that, following any termination of suspension, the Respondent's registration shall be placed on probation, with terms and conditions to be determined by the Board at that time, taking into account the findings of the evaluator;

**ORDERED** that the Consent Order is effective as of the date of its signing by the Board; and be it

**ORDERED** that the Respondent shall practice in accordance with the laws and regulations governing the practice of a pharmacy technician in Maryland; and be it further

**ORDERED** that, for purposes of public disclosure, as permitted by Md. General Provisions. Code Ann. §§ 4-101, *et seq.* (2014 Vol. and 2017 Supp.), this document consists of the contents of the foregoing Findings of Fact, Conclusions of Law and Order, and that the Board may also disclose same to any national reporting data bank that it is mandated to report to.

  
Kevin M. Morgan, Pharm.D. President  
State Board of Pharmacy

CONSENT OF RYANN TAYLOR, PHARM TECH

I, Ryann Taylor, Pharm Tech, acknowledge that I am represented by counsel, Paul Weber, Esquire, and have consulted with counsel before entering into this Consent Order.

By this Consent and for the purpose of resolving the issues raised by the Board, I agree and accept to be bound by the foregoing Consent Order and its conditions.

I acknowledge the validity of this Consent Order as if entered into after the conclusion of a formal evidentiary hearing in which I would have had the right to counsel, to confront witnesses, to give testimony, to call witnesses on my own behalf, and to all other substantive and procedural protections provided by the law. I agree to forego my opportunity to challenge these allegations. I acknowledge the legal authority and jurisdiction of the Board to initiate these proceedings and to issue and enforce this Consent Order. I affirm that I am waiving my right to appeal any adverse ruling of the Board that might have followed after any such hearing.

I sign this Consent Order, voluntarily and without reservation, after having an opportunity to consult with counsel, and I fully understand and comprehend the language, meaning and terms of this Consent Order.

4/16/18  
Date

  
Ryann Taylor, Pharm Tech



STATE OF Maryland :

CITY/COUNTY OF Anne Arundel :

I HEREBY CERTIFY that on this 16<sup>th</sup> day of April 2018, before me, Jayne Rampuro, a Notary Public of the foregoing State and (City/County), personally appeared Ryann Taylor, Pharm Tech, Registration No. T17843, and made oath in due form of law that signing the foregoing Consent Order was her voluntary act and deed, and the statements made herein are true and correct.

AS WITNESSETH my hand and notarial seal.

Jayne M. Rampuro  
Notary Public

My Commission Expires: 02/21/20